One potential advantage of CB-iNK T cells over AD-iNK T cells as the candidate for off the shelf cell therapy is their potential to regulate cytokine release syndrome given their ability to produce IL-10 and the enrichment of CD4+FoxP3+ cells (Figure 1D). Here, FOXP3 is linked to Alzheimer disease.